Lantern Pharma Inc. (LTRN)
Quote, stock score, analyst consensus, and SEC filings, plus insider and Congress trades when there are any.
NasdaqCM · Price as of · Nasdaq Real Time Price
- Profitability0/20
Losing money: $-18.5M net income over the last four reported quarters.
- Insider buying vs selling20/20
Insiders are net buyers: 4 open-market buys worth $200,001 vs 0 sells worth $0 across the last 2 Form 4 filings.
- Dilution and offerings1/15
Share count up 18.4% in a year and 4 offering-related filings. Heavy dilution. One nuance: offerings raise cash that can fund real growth. The score docks the certain near-term dilution; if the spending pays off, it shows up later in the profitability component.
- Analysts2
- Implied upside+2273.8%
- Target range$10.00 to $25.00
- EPS expected-$0.38
- A year ago-$0.39
LTRN closed at $0.64 on Oct 27, down 41.3% since Sep 28. Chart read: price below both the 50-day and 200-day moving averages; the 50-day is below the 200-day (downtrend structure); trading at 0% of the 52-week range ($0.62 to $4.17).
Insider buying and selling at Lantern Pharma Inc. (LTRN)
The most recent Form 4 on record for Lantern Pharma Inc. (LTRN) is May 12, 2026, when Lee Troy Schalop, Director, bought $100,001 of stock. An open-market purchase is money the filer chose to put in.
| Insider | Action | Value | Date | Type |
|---|---|---|---|---|
| Lee Troy Schalop · Director | Buy | $100,001 | May 12, 2026 | Notable buy |
| D Jeffrey Keyser · Director | Buy | $100,001 | May 12, 2026 | Notable buy |
SEC filings
| Form | Filed | Description |
|---|---|---|
| ARS | October 21, 2026 | ARS |
| DEF 14A | October 19, 2026 | DEF 14A |
| SCHEDULE 13G/A | October 13, 2026 | View on EDGAR |
| PRE 14A | October 8, 2026 | PRE 14A |
| 8-K | October 1, 2026 | 8-K |
| 8-K | September 30, 2026 | 8-K |
| 424B5 | September 30, 2026 | 424B5 |
| 8-K | September 24, 2026 | 8-K |
Frequently asked questions
When does LTRN report earnings?
Lantern Pharma Inc. (LTRN) is scheduled to report quarterly results on November 11, 2026, before the open. The 1-analyst consensus is -$0.38 per share for the quarter ended September 30, 2026, against -$0.39 a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters.
What do analysts expect for LTRN?
2 analysts cover Lantern Pharma Inc. (LTRN). No consensus rating has been published. The average price target is $17.50, in a range of $10.00 to $25.00.
Are insiders buying or selling LTRN?
We track Form 4 filings for Lantern Pharma Inc. (LTRN). The activity listed on this page shows 2 open-market purchases. Each row is labelled Routine when the filer declared a pre-arranged 10b5-1 plan, Tax withholding when shares were sold automatically to cover the tax on a vest, or Own call when neither applies.
Where can I see LTRN SEC filings?
Recent filings are listed on this page, newest first. The latest is an ARS filed October 21, 2026.